Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF + IL-12 genetically modified tumor cell vaccines

Cancer Gene Therapy

Volumn 20, Issue 10, 2013, Pages 576-581

  Miguel, A ^a   Herrero, M J ^a,b,c   Sendra, L ^a   Botella, R ^a,c   Algas R ^d   Sanchez M ^a   Alino S F ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Cancer vaccines; GM CSF; IL 12

Indexed keywords

GENETICALLY MODIFIED TUMOR CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; TUMOR CELL VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL COUNT; COMPARATIVE EFFECTIVENESS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG EFFICACY; EVALUATION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALIA; MURINAE; MUS;

ANIMALS; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-12; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 84886096502     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2013.54     Document Type: Article

References (39)

1. Nagai H, Oniki S, Fujiwara S, Yoshimoto T, Nishigori C. Antimelanoma immunotherapy: clinical and preclinical applications of IL-12 family members. Immunotherapy 2010; 2: 697-709.
2. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998; 91: 222-230. (Pubitemid 28018748)
3. Nemunaitis J, Sterman D, Jablons D, Smith 2nd JW, Fox B, Maples P et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004 326-331. (Pubitemid 38256277)
4. Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry Jr. WT. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J Immunother 2012; 35: 385-389.
5. Zhang X, Shi X, Li J, Hu Z, Zhou D, Gao J et al. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J Urol 2012; 187: 1071-1079.
6. Moret-Tatay I, Diaz J, Marco FM, Crespo A, Aliño SF. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene therapy 2003; 10: 887-897. (Pubitemid 37532335)
7. Herrero MJ, Botella R, Dasí F, Agás R, Sánchez M, Aliño SF. Antigens and cytokine genes in antitumor vaccines: the importance of the temporal delivery sequence in antitumor signals. Ann NY Acad Sci 2006; 1091: 412-424. (Pubitemid 47092254)
8. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol 2003; 21: 3343-3350. (Pubitemid 46606268)
9. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung K et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol 2003; 21: 624-630. (Pubitemid 46621895)
10. Olivares J, Kumar P, Yu Y, Maples PB, Senzer N, Bedell C et al. Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin Cancer Res 2011; 17: 183-192.
11. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13: 3883-3891. (Pubitemid 47037595)
12. Maio M, Fonsatti E, Lamaj E, Altomonte M, Cattarossi I, Santantonio C et al. Vaccination of stage IV patients with allogeneic IL-4-or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002; 51: 9-14. (Pubitemid 34158518)
13. Borrello I, Pardoll D. GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 2002; 13: 185-193. (Pubitemid 34229392)
14. Kang WK, Park C, Yoon HL, Kim WS, Yoon SS, Lee MH et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: outcome of a phase I study. Hum Gene Ther 2001; 12: 671-684. (Pubitemid 32506945)
15. Parney IF, Farr-Jones MA, Kane K, Chang LJ, Petruk KC. Human autologous in vitro models of glioma immunogene therapy using B7-2, GM-CSF and IL-12. Can J Neurol Sci 2002; 29: 267-275. (Pubitemid 34966323)
16. Heinzerling L, Burg G, Dummer R, Maier T, Oberholzer PA, Schultz J et al. Intratumoral injection of DNA encoding human interleukin-12 into patients with metastatic melanoma: clinical efficacy. Hum Gene Ther 2005; 16: 35-48. (Pubitemid 40250330)
17. Triozzi PI, Strong TV, Bucy RP, Allen KO, Carlisle RR, Moore SE et al. Intratumoral administration of a recombinant Canarypox virus expressing interleukin 12 in patients with metastatic melanoma. Hum Gene Ther 2005; 16: 91-100. (Pubitemid 40250335)
18. Sangro B, Melero I, Qian C, Prieto J. Gene therapy of cancer based on interleukin 12. Curr Gene Ther 2005; 5: 573-581. (Pubitemid 43009502)
19. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-5903.
20. Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK. IL-12+GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in her-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother 2006; 29: 10-20.
21. Choi KJ, Zhang SN, Choi IK, Kim JS, Yun CO. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther 2012; 19: 711-723.
22. Chang CJ, Chen YH, Huang KW, Cheng HW, Chan SF, Tai KF et al. Combined GMCSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors. Hepatology 2007; 45: 746-754.
23. Wang Z, Qiu SJ, Ye SL, Tang ZY, Xiao X. Combined IL-12 and GM-CSF gene therapy for murine hepatocellular carcinoma. Cancer Gene Ther 2001; 8: 751-758. (Pubitemid 32983131)
24. Qiu S, Ye S, Wang Z, Tang Z, Lu L, Xiao X. Study on the effects of combined IL-12 and GM-CSF gene therapy for murine liver cancer. Zhonghua Gan Zang Bing Za Zhi 2002; 10: 413-416.
25. Shi FS, Weber S, Gan J, Rakhmilevich AL, Mahvi DM. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF. Cancer Gene Ther 1999; 6: 81-88. (Pubitemid 129667762)
26. Guillem VM, Aliño SF. Transfection pathways of nonspecific and targeted PEIpolyplexes. Gene Ther Mol Biol 2004; 8: 369-384.
27. Serafini P, Carbley R, Noonan KA, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-6343. (Pubitemid 39129439)
28. Bordier C. Phase separation of integral membrane proteins in Triton X-114 solution. J Biol Chem 1981; 25: 1604-1607.
29. Terando AM, Faries MB, Morton DL. Vaccine therapy for melanoma: current status and future directions. Vaccine 2007; 25: B4-B16. (Pubitemid 47488552)
30. Zou W. Regulatory T cells, tumor immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
31. De Visser K, Eichten A, Coussens L. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37. (Pubitemid 43053650)
32. Nagai H, Horikawa T, Hara I, Fukunaga A, Oniki S, Oka M et al. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with IL-12 gene transfer. Exp Dermatol 2004; 13: 613-620. (Pubitemid 39345270)
33. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci 2009; 1174: 99-106.
34. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell Jr DJ et al. CD25 Blockade depletes and selectively reprograms regulatory T cells in concert with inmunotherapy in cancer patients. Sci Transl Med 2012; 4134ra62.
35. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736. (Pubitemid 26102823)
36. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011; 9: 196.
37. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, Ménégaux F et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009; 58: 520-529.
38. Frey AB. Myeloid supresor cells regulate the adaptive immune response to cancer. J Clin Invest 2006; 116: 2587-2590. (Pubitemid 44511621)
39. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al. Identification of a new subset of myeloid supresor cells in Peripherals blood of melanoma patients with modulation by a GM-CSF-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-2553. (Pubitemid 47041228)